Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

Podcast: Optimizing Management of Metastatic Squamous Non-Small Cell Lung Cancer

Access Activity

Overview / Abstract:

Discover new developments in the management of metastatic squamous non–small cell lung cancer (NSCLC), including individualized care plans, efficacy and safety of novel therapies, and strategies to optimize survivorship for patients with NSCLC. This activity is presented by expert faculty, Mark G. Kris, MD, Memorial Sloan Kettering Cancer Center, and Victoria Sherry, DNP, CRNP, AOCNP®, Nurse Practitioner, Abramson Cancer Center. Start the activity now.


Squamous cell lung carcinoma is a distinct histologic subtype of non–small cell lung cancer (NSCLC) that accounts for approximately 25% to 30% of all NSCLC cases and is associated with approximately 30% shorter survival compared with other subtypes of the disease. Because alterations and mutations for which targeted therapies are approved are uncommon in squamous cell NSCLC, treatment remains challenging. In addition, unique clinicopathologic characteristics and patient factors such as older age, advanced disease at diagnosis, and a higher incidence of comorbidities complicate effective treatment planning for patients with metastatic disease (Socinski et al, 2018). Therefore, it is essential that members of the multidisciplinary team maintain a comprehensive understanding of the efficacy and safety profiles of emerging therapies in order to inform treatment selection and adverse event management. In this activity, Mark G. Kris, MD, and Victoria Sherry, DNP, CRNP, AOCNP®, will update clinicians on strategies for developing personalized management plans to optimize the treatment and survivorship of patients with metastatic squamous cell NSCLC.


Oncologists, pulmonologists, nurse practitioners, physician assistants, oncology nurses, and other health care professionals involved in the treatment of patients with non-small cell lung cancer (NSCLC).


Upon completion of this activity, participants should be able to
Assess patient and tumor characteristics that can inform individualized management plans in metastatic NSCLC
Distinguish emerging efficacy and safety data on novel cytotoxic therapies, immunotherapies, and monoclonal antibodies for metastatic squamous NSCLC
Appraise strategies to control treatment-related adverse events and optimize survivorship in patients with metastatic squamous NSCLC


Feb 01, 2023


Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME



Credits / Hours




Presenters / Authors / Faculty

Mark G. Kris, MD
Attending Physician, Thoracic Oncology Service
William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center

Victoria Sherry, DNP, CRNP, AOCNP®
Nurse Practitioner
Abramson Cancer Center

Activity Specialities / Related Topics

Oncology / Cancer / Radiation Therapy

Sponsors / Supporters / Grant Providers

This activity is supported by an independent educational grant from Merck. Aggregate participant data will be shared with commercial supporters of this activity.

Keywords / Search Terms

i3 Health i3 Health i3 health, lung cancer, NSCLC, metastatic squamous non-small cell lung cancer, CNE, free CNE, free CE CME, free CE CME, free CE CME, NCPD, free NCPD, online NCPD, online NCPD, CME ,Free CE CME, Free CE CME, ANCC Free CE CME Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map